Bertin Daniel, Aghzadi Jehanne, Balandraud Nathalie, Roman Céline, Serrero Mélanie, Desplat-Jégo Sophie
Immunology Laboratory, Biogenopôle, Hôpital de la Timone, APHM, Marseille, France.
CNRS, INP, Institute of Neurophysiopathology, Aix-Marseille University, Marseille, France.
Clin Exp Immunol. 2025 Jan 21;219(1). doi: 10.1093/cei/uxae122.
Despite its wide use to treat various inflammatory diseases, infliximab becomes ineffective in some patients due to inadequate drug levels and production of anti-drug antibodies (ADA). The aim of this study was to compare the prevalence and ADA levels in a large cohort of patients. ADA and infliximab (IFX) through levels measured by enzyme-linked immunosorbent assay were collected from 505 patients within a period of 4 years. The results indicate that (i) 13.5% of patients produce ADA, (ii) male patients were more likely to produce ADA at levels above 10 000 ng/ml than female patients, (iii) ADA levels were lower when associated with immunosuppressant drugs, (iv) there was an inverse relationship between ADA presence and IFX detection, and (v) no correlation was observed between ADA levels and number of injections or brand of IFX administered. This study improves our understanding of the factors promoting IFX immunogenicity and highlights the need to develop personalized treatment strategies.
尽管英夫利昔单抗被广泛用于治疗各种炎症性疾病，但由于药物水平不足和抗药物抗体（ADA）的产生，在一些患者中它会变得无效。本研究的目的是比较一大群患者中ADA的患病率和水平。通过酶联免疫吸附测定法测量的ADA和英夫利昔单抗（IFX）水平是在4年内从505名患者中收集的。结果表明：（i）13.5%的患者产生ADA；（ii）男性患者比女性患者更有可能产生高于10000 ng/ml水平的ADA；（iii）与免疫抑制药物联合使用时ADA水平较低；（iv）ADA的存在与IFX检测之间呈负相关；（v）未观察到ADA水平与注射次数或所使用的IFX品牌之间存在相关性。这项研究增进了我们对促进IFX免疫原性因素的理解，并强调了制定个性化治疗策略的必要性。
